PTN Palatin Technologies Inc.

0.83
0  -0%
Previous Close 0.84
Open 0.84
Price To Book 1.89
Market Cap 188,964,862
Shares 227,039,363
Volume 474,994
Short Ratio 16.04
Av. Daily Volume 1,136,555
Stock charts supplied by TradingView

NewsSee all news

  1. Thinking about buying stock in Canopy Growth, Micron Technology, Palatin Technologies, SINTX Technologies, or Tilray?

    NEW YORK, Sept. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, MU, PTN, SINT, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

    CRANBURY, N.J., Sept. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the

  3. Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019

    CRANBURY, N.J., Sept. 11, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 before the open of the U.S.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced June 21, 2019.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Phase 2 trial to commence 1H 2019.
PL-3994
Heart failure
Phase 2 trial to commence 4Q 2019.
PL-8177
Non-infectious uveitis
Phase 2 trial to commence 1H 2020.
PL-8177
Ulcerative colitis

Latest News

  1. Thinking about buying stock in Canopy Growth, Micron Technology, Palatin Technologies, SINTX Technologies, or Tilray?

    NEW YORK, Sept. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, MU, PTN, SINT, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

    CRANBURY, N.J., Sept. 12, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the

  3. Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019

    CRANBURY, N.J., Sept. 11, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 before the open of the U.S.